STEPS TAKEN AFTER GRANTING THE MARKETING AUTHORISATION 
For procedures finalised after 1 June 2002 please refer to module 8B.  
• 
• 
• 
• 
• 
• 
On  08  January  1999,  the  Marketing  Authorisation  Holder  submitted  to  the  EMEA  an 
application for Telmisartan Boehringer Ingelheim Pharma KG 20 mg tablets, under Annex II to 
Commission  Regulation  (EC)  542/95  as  amended.  The  CPMP  recommended  the  approval  for 
this  additional  strength  and  adopted  an  opinion  on  20  May  1999.  The  respective  Commission 
Decision was issued on 07 September 1999. 
Pursuant to Article 10(3) of Council Directive No. 92/27/EEC of 31 March 1992, the Marketing 
Authorisation  Holder,  notified  the  EMEA on  26  February  1999  of their intention to introduce 
changes to an aspect of the labelling not connected to the Summary of Product Characteristics. 
The  Company  requested  additional  changes  on  8  March  and  27  April  1999.  (Changes  to  the 
Austrian contact address and the Danish contact fax number have been introduced. The section 
“Storage conditions” of the package leaflet has been amended in order to be consistent with the 
section  “Special  precautions  for  storage”  of  the  SPC.  Linguistic  corrections  have  been 
implemented into the German and Greek package leaflet.). On 30 April 1999, the EMEA hereby 
informs  the  European  Commission  that  the  above-mentioned  changes  are  accepted.  The 
respective Commission Decision was issued on 03 June 1999. 
The Marketing Authorisation Holder submitted to the EMEA on 8 March 1999 an application 
for  one  type  I  variation  falling  within  the  scope  of  item  No.  15  of  Annex  I  to  Commission 
Regulation (EC) No 542/95, as amended. The Marketing Authorisation Holder applied for: 
Several  minor  changes  to  the  manufacturing  process  of  the  finished  product,  including  an 
increase in batch size. 
On  19  April  1999,  the  EMEA  approved  the  variation.  This  variation  did  not  require 
amendments to the Commission Decision. 
The Marketing Authorisation Holder submitted to the EMEA on 8 March 1999 an application 
for  one  type  I  variation  falling  within  the  scope  of  item  No.  1  of  Annex  I  to  Commission 
Regulation (EC) No 542/95, as amended. The Marketing Authorisation Holder applied for: 
A change in the sites of the manufacture of spray-dried granulate. 
On  19  April  1999,  the  EMEA  approved  the  variation.  This  variation  did  not  require 
amendments to the Commission Decision. 
The Marketing Authorisation Holder submitted to the EMEA, between 6 September 1999 and 
19 November 1999, a number of applications for one type I variation falling within the scopes 
of item No 1, 12a, 14, 24a and 32 of Annex I to Commission Regulation (EC) No 542/95, as 
amended.  The Marketing Authorisation Holder applied for: 
- 
- 
- 
- 
Change of the manufacturing sites for part of the manufacturing process of the medicinal 
product. 
Change of imprints, bossing or other markings (except scoring) on tablets. 
Change in specification of starting material or intermediate used in the manufacture of the 
active substance (with Change in specification of active substance). 
Changes in test procedure for starting material or intermediate used in the manufacture of 
the active substance. 
Between  29  October  1999  and  15  March  2000,  the  EMEA  issued  the  corresponding 
notifications. These variations did not require amendments to the Commission Decision. 
The Marketing Authorisation Holder submitted to the EMEA on November 1999 an application 
of  one  type  I  variation  falling  within  the  scope  of  item  No  20  of  Annex  I  to  Commission 
Regulation (EC) No 542/95, as amended.  The Marketing Authorisation Holder applied for: 
An extension of shelf-life. 
1/2 
                  EMEA 2005 
 
 
 
 
 
 
• 
• 
On 17 December 1999, the EMEA issued the corresponding notification. The variation required 
amendments in the relevant sections of the Commission decision. The respective Commission 
Decision was issued on 09 March 2000. 
Pursuant to Article 10(3) of Council Directive No. 92/27/EEC of 31 March 1992, the Marketing 
Authorisation  Holder,  notified  the  EMEA  on  9  February  2000  of  their  intention  to  introduce 
changes  to  an  aspect  of  the  labelling  of  the  20  mg  strength  not  connected  to  the  Summary  of 
Product  Characteristic.  Changes  were  related  to  the  list  of  Marketing  Authorisation 
representatives  or  were  of  linguistic  nature.  On  21  February  2000,  the  EMEA  issued  the 
corresponding notification. The respective Commission Decision was issued on 30 March 2000. 
On  31st  January  2000,  the  Marketing  Authorisation  Holder  submitted  a  Type  II  variation 
application  in  accordance  with  Article  6  of  Commission  Regulation  (EC)  No.  542/95  of  10 
March 1995, as amended.  The scope of the variation related to the update of the SPC and PL of 
the 40 and 80 mg strengths to put them in line with the SPC and PL of the recently approved 20 
mg strength and with the latest QRD SPC/labelling/PL templates. In addition, the list has been 
updated.  During  the  assessment,  sections  on  pregnancy  and  interaction  with  food  have  been 
revised in order to be more accurate. 
On 12 April 2000, the CPMP approved the variation. The variation required amendments in the 
relevant  sections  of  the  Commission  Decision  and  the  EPAR.  The  European  commission 
amended the Decision on 13 July 2000. 
Subsequent post Marketing Authorisation applications agreed upon are summarised in the table below: 
Scope 
Application 
number 
Type of 
modification1 
Minor change of manufacturing process of the active substance 
With consequential change in test procedure for starting 
material/intermediate used in manuf. of active substance 
Batch size of active substance 
Change in test procedures of the medicinal product 
Changes in manufacture of the medicinal product 
Update of Summary of Product Characteristics and Package Leaflet 
The SPC was updated following the assessment of the 2nd and 3rd 
PSUR. 
Replacement of an excipient with a comparable excipient 
Extension of shelf-life as foreseen at time of authorisation 
Change in pack size for a medicinal product for 40 mg and 80 mg 
presentations. 
Update of the SPC and PL (point 4.4, 4.5, 4.8) 
I/0016 
I/0017 
I/0018 
I/0019 
II/0020 
I/0021 
I/0022 
I/0023 
II/0024 
I 
I  
I 
I 
II 
I 
I 
I 
II 
Notification/ 
Opinion 
issued on2 
02.08.00 
Commission 
Decision 
Issued/amended 
on 
N/A 
02.08.00 
14.08.00 
22.09.00 
N/A 
N/A 
N/A 
19.10.00 
22.01.01 
04.05.01 
N/A 
22.08.01 
19.10.01 
23.08.01 
19.10.01 
23.05.02 
30.05.02 
1  In  accordance  with  Commission  Regulation  (EC)  No.  542/95  of  10  March  1995,  as  amended:  I  refers  to  a 
minor  variation  (Type  I  variation);  II  refers  to  a  major  variation  (Type  II  variation);  I/II  refers  to  a  minor 
variation  following  the  procedure  set  out  in  Article  6,  7  and  8  of  the  Regulation;  X  refers  to  an  Annex  II 
application. 
T refers to a transfer of a Marketing Authorisation in accordance with Commission Regulation (EC) No 2141/96 
of 7 November 1996.  
N refers to a notification in accordance with Article 10(3) of Council Directive 92/27/EEC of 31 March 1992. 
2 For Notifications and Type I variations, the date of entry into force of the change is the EMEA Notification 
date. The Commission Decision will be amended accordingly. 
2/2 
                  EMEA 2005 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                            
 
